{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:18:00Z","timestamp":1762543080598},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41433-019-0539-3","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T17:02:40Z","timestamp":1564419760000},"page":"515-522","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["An audit of retinal lymphoma treatment at the University of California San Francisco"],"prefix":"10.1038","volume":"34","author":[{"given":"Bertil","family":"Damato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg J.","family":"Bever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin R.","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"key":"539_CR1","first-page":"283","volume":"6","author":"I Araujo","year":"2017","unstructured":"Araujo I, Coupland SE. Primary vitreoretinal lymphoma\u2013a review. Asia Pac J Ophthalmol (Philos). 2017;6:283\u20139.","journal-title":"Asia Pac J Ophthalmol (Philos)"},{"key":"539_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1076\/ocii.8.4.243.6463","volume":"8","author":"N Cassoux","year":"2000","unstructured":"Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Milea D, Gerber S, et al. Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm. 2000;8:243\u201350.","journal-title":"Ocul Immunol Inflamm"},{"key":"539_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaophthalmol.2013.569","volume":"131","author":"SD Levasseur","year":"2013","unstructured":"Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol. 2013;131:50\u20135.","journal-title":"JAMA Ophthalmol"},{"key":"539_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.14025","volume":"173","author":"F Fend","year":"2016","unstructured":"Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol. 2016;173:680\u201392.","journal-title":"Br J Haematol"},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T, Shalom E, Pe\u2019er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383\u20138.","journal-title":"Br J Ophthalmol"},{"key":"539_CR6","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.eye.6702437","volume":"21","author":"A Berenbom","year":"2007","unstructured":"Berenbom A, Davila RM, Lin HS, Harbour JW. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye. 2007;21:1198\u2013201.","journal-title":"Eye"},{"key":"539_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","volume":"98","author":"KL Larkin","year":"2014","unstructured":"Larkin KL, Saboo US, Comer GM, Forooghian F, Mackensen F, Merrill P, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98:99\u2013103.","journal-title":"Br J Ophthalmol"},{"key":"539_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaophthalmol.2017.1810","volume":"135","author":"CL Shields","year":"2017","unstructured":"Shields CL, Sioufi K, Mashayekhi A, Shields JA. Intravitreal melphalan for treatment of primary vitreoretinal lymphoma: a new indication for an old drug. JAMA Ophthalmol. 2017;135:815\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"539_CR9","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16:1589\u201399.","journal-title":"Oncologist"},{"key":"539_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/107327481602300204","volume":"23","author":"MT Witmer","year":"2016","unstructured":"Witmer MT. Primary vitreoretinal lymphoma: management of isolated ocular disease. Cancer Control. 2016;23:110\u20136.","journal-title":"Cancer Control"},{"key":"539_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00417-004-0947-2","volume":"242","author":"K Jahnke","year":"2004","unstructured":"Jahnke K, Bechrakis NE, Coupland SE, Schmittel A, Foerster MH, Fischer L, et al. Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature. Graefe\u2019s Arch Clin Exp Ophthalmol. 2004;242:771\u20136.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"539_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/10428199609054837","volume":"23","author":"C Soussain","year":"1996","unstructured":"Soussain C, Merle-Beral H, Reux I, Sutton L, Fardeau C, Gerber S, et al. A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases. Leuk lymphoma. 1996;23:339\u201345.","journal-title":"Leuk lymphoma"},{"key":"539_CR13","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.ophtha.2016.03.043","volume":"123","author":"DT Nguyen","year":"2016","unstructured":"Nguyen DT, Houillier C, Choquet S, Cassoux N, Soussain C, Le Cossec C, et al. Primary oculocerebral lymphoma: MTX polychemotherapy alone on intraocular disease control. Ophthalmology. 2016;123:2047\u201350.","journal-title":"Ophthalmology"},{"key":"539_CR14","first-page":"711","volume":"9","author":"TT Batchelor","year":"2003","unstructured":"Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003;9:711\u20135.","journal-title":"Clin Cancer Res"},{"key":"539_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1365-2141.2004.05028.x","volume":"126","author":"A Hormigo","year":"2004","unstructured":"Hormigo A, Abrey L, Heinemann MH, DeAngelis LM. Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol. 2004;126:202\u20138.","journal-title":"Br J Haematol"},{"key":"539_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00006982-199515020-00006","volume":"15","author":"S Valluri","year":"1995","unstructured":"Valluri S, Moorthy RS, Khan A, Rao NA. Combination treatment of intraocular lymphoma. Retina. 1995;15:125\u20139.","journal-title":"Retina"},{"key":"539_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00417-014-2584-8","volume":"252","author":"N Hashida","year":"2014","unstructured":"Hashida N, Nakai K, Saitoh N, Nishida K. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma. Graefe\u2019s Arch Clin Exp Ophthalmol. 2014;252:687\u201393.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"539_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00417-005-0138-9","volume":"244","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Korfel A, Komm J, Bechrakis NE, Stein H, Thiel E, et al. Intraocular lymphoma 2000\u20135: results of a retrospective multicentre trial. Graefe\u2019s Arch Clin Exp Ophthalmol. 2006;244:663\u20139.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"539_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/COC.0000000000000028","volume":"39","author":"MM Kim","year":"2016","unstructured":"Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, et al. Survival outcomes of primary intraocular lymphoma: a single-institution experience. Am J Clin Oncol. 2016;39:109\u201313.","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"539_CR20","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjophthalmol-2017-311574","volume":"102","author":"Aneta Klimova","year":"2018","unstructured":"Klimova A, Heissigerova J, Rihova E, Brichova M, Pytlik R, Spicka I et al. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse. Br J Ophthalmol 2018;102:1579\u201385.","journal-title":"British Journal of Ophthalmology"},{"key":"539_CR21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00277-015-2582-x","volume":"95","author":"WL Ma","year":"2016","unstructured":"Ma WL, Hou HA, Hsu YJ, Chen YK, Tang JL, Tsay W, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. Ann Hematol. 2016;95:593\u2013601.","journal-title":"Ann Hematol"},{"key":"539_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","volume":"133","author":"A Riemens","year":"2015","unstructured":"Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015;133:191\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"539_CR23","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","volume":"18","author":"SA Grimm","year":"2007","unstructured":"Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, et al. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol. 2007;18:1851\u20135.","journal-title":"Ann Oncol"},{"issue":"3","key":"539_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/09273948.2017.1421669","volume":"26","author":"Bum-Joo Cho","year":"2018","unstructured":"Cho BJ, Kim DY, Park UC, Lee JY, Yoon YH, Yu HG. Clinical features and treatment outcomes of vitreoretinal lymphoma according to its association with CNS lymphoma. Ocul Immunol Inflamm 2018;26:1\u20137.","journal-title":"Ocular Immunology and Inflammation"},{"key":"539_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/01.wnl.0000327672.04729.8c","volume":"71","author":"SA Grimm","year":"2008","unstructured":"Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71:1355\u201360.","journal-title":"Neurology"},{"key":"539_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/annonc\/mdf080","volume":"13","author":"AJ Ferreri","year":"2002","unstructured":"Ferreri AJ, Blay JY, Reni M, Pasini F, Gubkin A, Tirelli U, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol. 2002;13:531\u20138.","journal-title":"Ann Oncol"},{"key":"539_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/bjophthalmol-2017-311151","volume":"102","author":"J Gonzales","year":"2018","unstructured":"Gonzales J, Doan T, Shantha JG, Bloomer M, Wilson MR, DeRisi JL, et al. Metagenomic deep sequencing of aqueous fluid detects intraocular lymphomas. Br J Ophthalmol. 2018;102:6\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"539_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000487949","volume":"5","author":"Bertil\u00a0E. Damato","year":"2018","unstructured":"Damato BE, Bever GJ, Afshar AR, Rubenstein JL. Insights from a Case of Vitreoretinal Lymphoma. Ocul Oncol Pathol. 2019:13\u20139. https:\/\/doi.org\/10.1159\/000487949 .","journal-title":"Ocular Oncology and Pathology"},{"key":"539_CR29","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.hoc.2016.07.013","volume":"30","author":"J Carnevale","year":"2016","unstructured":"Carnevale J, Rubenstein JL. The challenge of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2016;30:1293\u2013316.","journal-title":"Hematol Oncol Clin North Am"},{"key":"539_CR30","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1200\/JCO.2011.34.7252","volume":"29","author":"JL Rubenstein","year":"2011","unstructured":"Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011;29:e595\u20137.","journal-title":"J Clin Oncol"},{"key":"539_CR31","doi-asserted-by":"publisher","unstructured":"Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE. Therapeutic vitrectomy as an adjunct treatment to systemic chemotherapy for intraocular lymphoma. Retin Cases Brief Rep 2017. https:\/\/doi.org\/10.1097\/ICB.0000000000000668 .","DOI":"10.1097\/ICB.0000000000000668"},{"key":"539_CR32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4103\/0973-1482.140824","volume":"11","author":"P Venkatesh","year":"2015","unstructured":"Venkatesh P, Gogia V, Khanduja S, Gupta S, Kumar L, Garg S. Therapeutic vitrectomy for vitreal recurrence of intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy. J Cancer Res Ther. 2015;11:668.","journal-title":"J Cancer Res Ther"},{"key":"539_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/jamaophthalmol.2017.0464","volume":"135","author":"A Pakdel","year":"2017","unstructured":"Pakdel A, Mammo Z, Hollands H, Forooghian F. Regression of subretinal lymphoma after diagnostic vitrectomy. JAMA Ophthalmol. 2017;135:503\u20135.","journal-title":"JAMA Ophthalmol"},{"key":"539_CR34","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.eye.6700378","volume":"17","author":"PM Hoffman","year":"2003","unstructured":"Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye. 2003;17:513\u201321.","journal-title":"Eye"},{"key":"539_CR35","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0161-6420(02)01125-9","volume":"109","author":"JR Smith","year":"2002","unstructured":"Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709\u201316.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-019-0539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-019-0539-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-019-0539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T13:18:21Z","timestamp":1721567901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-019-0539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1038\/s41433-019-0539-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"3 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"\u00a0JLR receives research funding from Genentech and Celgene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}